Litcius/Paper detail

Myocardial 2D Strain During Long-Term (>5 Years) Follow-Up of Childhood Survivors of Acute Lymphoblastic Leukemia Treated With Anthracyclines

Milanthy S. Pourier, Annelies M. C. Mavinkurve‐Groothuis, Myrthe M. Dull, Gert Weijers, Jacqueline J. Loonen, Louise Bellersen, Chris L. de Korte, Livia Kapusta

2020The American Journal of Cardiology16 citationsDOIOpen Access PDF

Abstract

), shortly after (T = 2) and long after anthracycline treatment (T = 3, ≥5 years after anthracycline exposure). Cardiac function of survivors at the latest follow up was compared with 70 healthy age-matched controls. None of the survivors showed clinical signs of cardiac failure at T = 3. Strain values decreased during anthracycline treatment and an ongoing reduction was seen at the latest follow-up (T = 3) with preserved cardiac function (normal ejection fraction and shortening fraction). At T = 1, a relative reduction in longitudinal strain (≥10% compared with baseline) was observed in 38% of the survivors, which increased to 54% at T=3. ALL survivors showed significantly lower conventional and myocardial 2D strain values, especially strain rate, compared with healthy age-matched controls. At T = 3, we did not find any abnormal cardiac troponin T levels. Six percent of the survivors showed abnormal N-terminal-pro-brain natriuretic peptide levels. This prospective study showed an ongoing reduction of 2D myocardial strain and strain rate, with preserved left ventricular ejection fraction (≤10% decrease compared with baseline) in asymptomatic ALL survivors at late follow-up.

Topics & Concepts

AnthracyclineMedicineEjection fractionCardiotoxicitySubclinical infectionInternal medicineCardiologyHeart failureCardiac function curveNatriuretic peptideTroponin TTroponinChemotherapyMyocardial infarctionCancerBreast cancerChemotherapy-induced cardiotoxicity and mitigationChildhood Cancer Survivors' Quality of LifeHeart Failure Treatment and Management